Evaluation changes in indicators of oncological service in GASTRIC cancer in Kazakhstan

Authors

  • Rustem S TASZHANOV Astana Medical University
  • Nurbek S IGISSINOV International Higher School of Medicine
  • Saken K KOZHAKHMETOV Astana Medical University
  • Sarsenbi KOBLANDIN Astana Medical University
  • Gulnur S IGISSINOVA Central Asian Cancer Institute
  • Zarina A BILYALOVA Central Asian Cancer Institute
  • Dariyana M KULMIRZAYEVA Asfendiyarov Kazakh National Medical University

DOI:

https://doi.org/10.31082/1728-452X-2020-211-212-1-2-21-25

Keywords:

gastric cancer, incidence, mortality, early diagnosis, neglect, morphological verification

Abstract

About 1.8 million new cases of gastric cancer (GC) are predicted and it is expected that about 1.4 million human will die from this pathology, according to the forecasts of the International Agency for Research on Cancer in 2040. To this aim, an analysis studying the indicators of the oncological service for GC also makes it possible to evaluate the ongoing anti-cancer measures in the Republic of Kazakhstan.
Aim. Evaluate some indicators of the oncological service at GC in Kazakhstan in 2009 to 2018.
Material and methods. The research material was data from the Ministry of Health of the Republic of Kazakhstan – annual form No. 7 and 35 regarding GC (ICD 10-C50) for 2009-2018 – incidence, mortality, early diagnosis, neglect, morphological verification. A retrospective study using descriptive and analytical methods of biomedical statistics was used as the main method.
Results and discussion. For 2009-2018, 27,468 new cases of GC were registered in the republic for the first time and 19,672 deaths from this pathology were registered. The average annual crude incidence rate of GC was 16.1±0.20/0000 (95% CI=15.7-16.5) and decreased in dynamics from 16.8±0.30/0000 (2009) to 15.1±0.30/0000 in 2018, the difference was statistically significant (t=4.01 and p=0.000). In dynamics, mortality rates from GC tended to statistically significant (t=12.02 and p=0.000) decrease from 14.0±0.30/0000 (2009) to 8.9±0.20/0000 in 2018 year, and the average annual crude mortality rate from GC was 11.6±0.60/0000 (95% CI=10.5-12.7). The research of the study period reveals a trend: early diagnosis indicators (specific weight of patients with I-II stage) improved from 24.5% (2009) to 41.3% in 2018, and accordingly the specific weight of neglected patients significantly decreased with stage III (from 46.2% to 41.1%) and with stage IV (from 29.3% to 17.5%). The morphological verification indicators for GC over the studied years improved from 85.1% to 95.0%.
Conclusion. An analysis of the indicators of the oncological service in GC revealed an improvement in morphological verification and early diagnosis, a decrease in neglect and mortality rates, which is undoubtedly associated with ongoing anti-cancer measures in Kazakhstan, in particular with the screening, which was carried out in 2012-2016.

References

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed 19 December 2019.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492. PMID:30207593

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144(8):1941–1953. https://doi.org/10.1002/ijc.31937 PMID:30350310

Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148(4):719-31.e3. DOI: 10.1053/j.gastro.2015.01.040.

Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. DOI: 10.1136/gutjnl-2015-309252.

Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49(1):1–8. DOI: 10.1007/s00535-013-0897-8

Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013;132(6):1272-6. DOI: 10.1002/ijc.27965

Schistosomes, Liver Flukes and Helicobacter Pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241. PMID: 7715068

Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487-90. DOI: 10.1002/ijc.28999

Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol. 2010;45(1):1-8. DOI:10.1007/s00535-009-0117-8

Rugge M. Gastric cancer risk in patients with Helicobacter pylori infection and following its eradication. Gastroenterol Clin N Am. 2015;44(3):609-24. DOI:10.1016/j.gtc.2015.05.009

Merkov AM, Polyakov LE. Sanitarnaya statistika [Sanitary statistics]. Leningrad: Medicine; 1974. 384 p.

Glanc S. Mediko-biologicheskaya statistika [Biomedical statistics]. Moscow: Practice; 1999. 460 p.

Published

2020-02-07

Issue

Section

Articles

Most read articles by the same author(s)